Johnathan Alexander Khusid

Johnathan Alexander Khusid

Auto-generated profile, based on publicly available information

Johnathan Alexander Khusid

Department of Urology, Icahn School of Medicine at Mount Sinai, New York, New York, USA

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 May 2020 in International Journal Of Clinical Practice
Verified
Journal Article
Closed access
PDF file
JKJohnathan A. Khusid
Johnathan A. Khusid
CWCorey S. Weinstein
Corey S. Weinstein
ABAdan Z. Becerra
Adan Z. Becerra
MKMahyar Kashani
Mahyar Kashani
DRDennis J. Robins
Dennis J. Robins
JWJeffrey P. Weiss
Jeffrey P. Weiss

20 July 2021 in Cell Communication and Signaling
Verified
Journal Article
Open access
PDF file
MAMaddison Archer
Maddison Archer
Navneet DograNavneet Dogra
Navneet Dogra
ZDZ. Dovey
Z. Dovey
TGT. Ganta
T. Ganta
HJH.-S. Jang
H.-S. Jang
Natasha KyprianouNatasha Kyprianou
Natasha Kyprianou
The urinary tract is highly innervated by autonomic nerves which are essential in urinary tract development, the production of growth factors, and the control of homeostasis. These neural signals may become dysregulated in several genitourinary (GU) disease states, both benign and malignant. Accordingly, the autonomic nervous system is a therapeutic target for several genitourinary pathologies including cancer, voiding dysfunction, and obstructing nephrolithiasis. Adrenergic receptors (adrenoceptors) are G-Protein coupled-receptors that are distributed throughout the body. The major function of α1-adrenoceptors is signaling smooth muscle contractions through GPCR and intracellular calcium influx. Pharmacologic intervention of α-and β-adrenoceptors is routinely and successfully implemented in the treatment of benign urologic illnesses, through the use of α-adrenoceptor antagonists. Furthermore, cell-based evidence recently established the antitumor effect of α1-adrenoceptor antagonists in prostate, bladder and renal tumors by reducing neovascularity and impairing growth within the tumor microenvironment via regulation of the phenotypic epithelial-mesenchymal transition (EMT). There has been a significant focus on repurposing the routinely used, Food and Drug Administration-approved α1-adrenoceptor antagonists to inhibit GU tumor growth and angiogenesis in patients with advanced prostate, bladder, and renal cancer. In this review we discuss the current evidence on (a) the signaling events of the autonomic nervous system mediated by its cognate α- and β-adrenoceptors in regulating the phenotypic landscape (EMT) of genitourinary organs; and (b) the therapeutic significance of targeting this signaling pathway in benign and malignant urologic disease.

9 August 2021 in Frontiers in Surgery
Verified
Journal Article
Open access
JKJohnathan A. Khusid
Johnathan A. Khusid
JHJohn C. Hordines
John C. Hordines
ASAreeba S. Sadiq
Areeba S. Sadiq
WAWilliam M. Atallah
William M. Atallah
MGMantu Gupta
Mantu Gupta
Kidney stone disease (KSD) is a commonly encountered ailment in urologic practice. Urinary tract infection (UTI) is commonly associated with KSD, both as an etiology (e.g., struvite and carbonate apatite stones), and as a complication (i.e., obstructive pyelonephritis and post-operative UTI). Indeed, a significant portion of the economic burden of KSD is skewed toward stones associated with infection. UTI is the most common post-operative complication related to stone intervention with progression to urosepsis as a rare but serious consequence. Risk for infection is influenced by a variety of factors including co-morbid conditions, anatomic abnormalities, prior surgical procedures, and local anti-microbial susceptibility. Understanding these risks and the proper steps to mitigate them is an essential component in reducing post-operative morbidity and mortality. Retrograde intrarenal surgery is routinely used for the treatment of KSD. The objective of this review article is to examine the current literature and guidelines for the prevention and management of stone-related infectious complications associated with retrograde intrarenal surgery. Special attention will be given to the incidence, etiology, and antibiotic prophylaxis choice in the management of stone-related infections. Intraoperative risk mitigation techniques will be discussed in conjunction with the management of post-operative infections. Antibiotic stewardship and the potential benefits of reduced empiric antibiotic treatment will also be discussed.

1 January 2021 in Investigative and Clinical Urology
Verified
Journal Article
Open access
PDF file
JKJohnathan A. Khusid
Johnathan A. Khusid
RKRaymond Khargi
Raymond Khargi
BSBenjamin Seiden
Benjamin Seiden
ASAreeba S. Sadiq
Areeba S. Sadiq
WAWilliam M. Atallah
William M. Atallah
MGMantu Gupta
Mantu Gupta
Khusid JA, et al. Investig Clin Urol. 2021 Mar;62(2):136-147. https://doi.org/10.4111/icu.20200467

1 April 2022 in Journal of Endourology
Verified
Journal Article
Closed access
ABAdan Zapien Becerra
Adan Zapien Becerra
JKJohnathan Alexander Khusid
Johnathan Alexander Khusid
MSMorgan R. Sturgis
Morgan R. Sturgis
LFLauren E. Fink
Lauren E. Fink
MGMantu Gupta
Mantu Gupta
EOEphrem O. Olweny
Ephrem O. Olweny
Background: The U.S. health care landscape has witnessed numerous changes since implementation of the Affordable Care Act coupled with rising prevalence of upper urinary tract stone disease (SD). Data on the economic burden of SD during this period are lacking, providing the objective of our study. Materials and Methods: Adults diagnosed as having SD from 2011 to 2018 were identified from PearlDiver Mariner, a national all-payer database reporting reimbursements and prescription costs for all health care encounters. Patients undergoing operative and nonoperative care were identified. Time trends in annual expenditures were evaluated. Multivariable analysis evaluated determinants of spending. Results: A total of $10 billion were spent on SD management between 2011 and 2018 (median overall annual expenditure = $1.4 billion) among 786,756 patients. Inpatient, prescription, and outpatient costs accounted for 34.7%, 20.7%, and 44.6% of expenditures, respectively. Seventy-eight percent of patients were managed nonoperatively (total cost = $6.9 billion). The average overall cost per encounter was $13,587 ($17,102 for surgical vs $11,174 for nonsurgical care). Expenditures on inpatient care decreased significantly over time, while expenditures on prescriptions and outpatient care increased significantly. On multivariable analysis, a higher Charlson Comorbidity Index (CCI) was associated with higher spending, while associations for age, insurance, and region varied by treatment modality. Conclusions: The economic burden of SD management is substantial, dominated by expenditure on nonoperative management and outpatient care. Expenditures for prescription and outpatient care are rising, with the only consistent predictor of higher spending being CCI. Spending variation according to demographic, clinical, and geographic factors was evident.

1 August 2024 in Journal of Endourology
Verified
Journal Article
Closed access
CCChristopher Connors
Christopher Connors
KGKavita Gupta
Kavita Gupta
JKJohnathan Alexander Khusid
Johnathan Alexander Khusid
RKRaymond Khargi
Raymond Khargi
AYAlan J. Yaghoubian
Alan J. Yaghoubian
MGMantu Gupta
Mantu Gupta
Introduction: Artificial intelligence (AI) platforms such as ChatGPT and Bard are increasingly utilized to answer patient health care questions. We present the first study to blindly evaluate AI-generated responses to common endourology patient questions against official patient education materials. Methods: Thirty-two questions and answers spanning kidney stones, ureteral stents, benign prostatic hyperplasia (BPH), and upper tract urothelial carcinoma were extracted from official Urology Care Foundation (UCF) patient education documents. The same questions were input into ChatGPT 4.0 and Bard, limiting responses to within ±10% of the word count of the corresponding UCF response to ensure fair comparison. Six endourologists blindly evaluated responses from each platform using Likert scales for accuracy, clarity, comprehensiveness, and patient utility. Reviewers identified which response they believed was not AI generated. Finally, Flesch–Kincaid Reading Grade Level formulas assessed the readability of each platform response. Ratings were compared using analysis of variance (ANOVA) and chi-square tests. Results: ChatGPT responses were rated the highest across all categories, including accuracy, comprehensiveness, clarity, and patient utility, while UCF answers were consistently scored the lowest, all p < 0.01. A subanalysis revealed that this trend was consistent across question categories (i.e., kidney stones, BPH, etc.). However, AI-generated responses were more likely to be classified at an advanced reading level, while UCF responses showed improved readability (college or higher reading level: ChatGPT = 100%, Bard = 66%, and UCF = 19%), p < 0.001. When asked to identify which answer was not AI generated, 54.2% of responses indicated ChatGPT, 26.6% indicated Bard, and only 19.3% correctly identified it as the UCF response. Conclusions: In a blind evaluation, AI-generated responses from ChatGPT and Bard surpassed the quality of official patient education materials in endourology, suggesting that current AI platforms are already a reliable resource for basic urologic care information. AI-generated responses do, however, tend to require a higher reading level, which may limit their applicability to a broader audience.